| 词条 | Olokizumab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 458283465 | type = mab | image = | alt = | mab_type = mab | source = zu | target = IL6 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1007223-17-7 | UNII_Ref = {{fdacite|changed|FDA}} | UNII = PAI71R1D2W | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | chemical_formula = | molecular_weight = }} Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA). It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe RA.[2][3] References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}} {{Monoclonals for immune system}}{{Interleukin receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^Another IL-6 Blocker in RA 3. ^{{Cite journal|url = http://ard.bmj.com/content/73/9/1607.abstract|title = Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study|last = Genovese|first = MC|date = 2014|journal = Ann Rheum Dis|doi = 10.1136/annrheumdis-2013-204760|pmid = |access-date = 21 February 2016|pmc = 4145439}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。